Treatment Guidelines from The Medical Letter
FROM
ISSUE
120
Antifungal Drugs
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The drugs of choice for treatment of fungal infections are listed in Table 1. Some of the indications and dosages recommended here have not been approved by the FDA. More detailed guidelines for some of these infections are available online from the Infectious Diseases Society of America (www.idsociety.org).

AZOLES

Azole antifungal agents inhibit synthesis of ergosterol, an essential component of the fungal cell membrane. They vary in their spectrum of activity, oral bioavailability, adverse effects and potential for drug-drug interactions.

FLUCONAZOLE — Fluconazole (Diflucan, and others) is active against most Candida species other than C. krusei, which is intrinsically resistant, and many strains of C. glabrata, which are variably resistant. It has good activity ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Antifungal Drugs
Article code: 120a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian